- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04120805
Random Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy
November 27, 2023 updated by: University of Chicago
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy
The purpose of this study is to evaluate the necessity of using hemostatic agents as a tool when performing robotic partial nephrectomy in the treatment of kidney cancer.
This project asks whether patients who undergo robotic partial nephrectomy without the surgeon using hemostatic agents during the procedure will have the same, fewer, or more complications than when patients undergo this same surgery with the surgeon using hemostatic agents during the procedure.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
178
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Arieh Shalhav, MD
- Phone Number: 773-834-9889
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- The University of Chicago
-
Contact:
- Arieh Shalhav, MD
- Phone Number: 773-834-9889
-
Principal Investigator:
- Arieh Shalhav, MD
-
Principal Investigator:
- Scott Eggener, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male and female patients aged 18 years and older.
- Patients must have a solid or cystic renal mass suspicious for malignancy by imaging with ultrasound, computed tomography (CT) scan, or magnetic resonance imaging (MRI).
- Patients must be initially scheduled RALPN as opposed to radical nephrectomy or other techniques for partial nephrectomy such as open surgery or pure laparoscopy without robot assistance.
- Patients with bilateral kidneys or a solitary kidney, so long as these are native kidneys as opposed to a transplanted kidney.
- Patients can have the common single renal artery and single renal vein, or they can have common variants such as two renal arteries and/or two renal veins.
Exclusion Criteria:
- Patients on hemodialysis.
- Patients who have had a renal transplantation.
- Patients on therapeutic anticoagulation prior to surgery (example anticoagulants include: aspirin 325 mg daily, clopidogrel, warfarin, fondaparinux, dabigatran, and rivaroxaban). However, patients who take aspirin 81 mg daily as their daily regimen will be included.
- Patients with bleeding disorders (example: hemophilia) and other documented coagulopathy (example: chronic liver disease) with INR greater than 1.0 at baseline.
- Patients who have had a prior surgical procedure, aside from percutaneous renal biopsy, on the kidney in the current operation.
- Patients with over 100 mL of estimated blood loss (calculated by anesthesia team using the suction canisters) prior to clamping of the renal hilum will be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (Hemostatic Agents Plus +)
|
Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
|
Active Comparator: Group 2 (Hemostatic Agents Negative -)
No Hemostatic Agent
|
Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
An absolute change in hemoglobin
Time Frame: up to 6 months
|
The change in hemoglobin will be measured as the difference between the hemoglobin obtained postoperatively and the hemoglobin obtained preoperatively.
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total number of major bleeding complications
Time Frame: up to 6 months
|
Major complications are blood loss requiring transfusion of packed red blood cells, reoperation and endovascular ablation
|
up to 6 months
|
Safety monitoring parameters: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: up to 6 months
|
Safety monitoring parameters including stroke, death, cardiac arrest, myocardial infarction and urine leak
|
up to 6 months
|
Operating room parameters
Time Frame: up to 6 months
|
Operating room parameters including number of sutures used during renorrhaphy and capsular closure, duration of renorrhaphy and patients in group 2 with no hemostatic agents who required HA at the surgeons discretion
|
up to 6 months
|
Patients with a hospital stay over 30 days
Time Frame: up to 6 months
|
Total length of all inpatient hospital stay over 30 days measured in days
|
up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Arieh Shalhav, MD, University of Chicago
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2016
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
March 1, 2026
Study Registration Dates
First Submitted
January 14, 2019
First Submitted That Met QC Criteria
October 7, 2019
First Posted (Actual)
October 9, 2019
Study Record Updates
Last Update Posted (Actual)
November 29, 2023
Last Update Submitted That Met QC Criteria
November 27, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB15-0519
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Cancer
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnKidney/Urinary Cancer
-
PfizerCompletedKidney Cancer | Kidney Neoplasms | Renal Cell Carcinoma | Renal Cancer | Renal Cell Cancer | Cancer of the Kidney | Cancer of KidneyFinland
-
Tianjin Medical University Second HospitalRecruiting
-
Tianjin Medical University Second HospitalRecruiting
-
Cedars-Sinai Medical CenterRecruitingProstate Cancer Stage II | Prostate Cancer Stage I | Bladder Cancer Stage II | Kidney Cancer Stage IUnited States
-
Intuitive SurgicalCompleted
-
Dana-Farber Cancer InstituteCompletedKidney Cancer | Prostate Cancer | Genitourinary CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedKidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IVUnited States
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
Clinical Trials on Hemostatic Agent
-
PROCEPT BioRoboticsCompletedBenign Prostatic HyperplasiaIndia
-
General University Hospital, PragueRecruitingComplication of Treatment | Biliary ObstructionCzechia
-
Thrombotargets Europe S.LCompletedBurns | Traumatic LesionsSpain
-
Hospital for Special Surgery, New YorkBaxter Healthcare CorporationCompleted
-
Medical University of ViennaCompleted
-
The University of Texas Health Science Center at...RecruitingPalatal Donor Site Wound Healing Following Periodontal Plastic Surgery Using Amnion-Chorion MembranePalate; WoundUnited States
-
Krishnadevaraya College of Dental Sciences & HospitalCompleted
-
Cukurova UniversityCompleted
-
Seoul National University HospitalRecruitingBenign Ovarian CystKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenUnknownAppetite RegulationBelgium